Experiments on APPswe/PS1dE9 mice (Alzheimer’s disease model) suggested that colivelin treatment improve the cognitive and behavioural functions and reduced Aβ deposition in the hippocampus in APP/PS1 mice [109]. This evidence concerns the gene PSEN1 and early-onset autosomal dominant Alzheimer disease.